Accès ouvert
2024
conference-abstract
OpenAlex
Philipp Nakov, Daniela Drandi, Lisa Kaiser, Dajana Kaszynski et autres
Background: In Waldenström Macroglobulinemia (WM) genetic alterations such as MYD88, CXCR4 and TP53 mutations can affect treatment outcome in the era of Bruton's tyrosine kinase inhibitors, highlighting the importance of understanding the molecular landscape in this disease. Liquid biopsy and the analysis …
de, it, gr
(code pays fourni par la source)
2024
conference-abstract
OpenAlex
Christian Buske, Efstathios Kastritis, Alexander Grunenberg, Andreas Viardot et autres
Background:Covalent BTK inhibitors are the backbone of treatment for patients with Waldenström's Macroglobulinemia (WM). Addition of rituximab to ibrutinib has shown a remarkable efficacy in WM in the iNNOVATE trial, including patients carrying CXCR4 mutations or MYD88 wildtype (Dimopoulos et al, NEJM …
de, gr, it
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Shiva Bamezai, Alex Jose Pulikkottil, Tribhuwan Yadav, Vegi M. Naidu et autres
RNA-binding proteins (RBPs) form a large and diverse class of factors, many members of which are overexpressed in hematologic malignancies. RBPs participate in various processes of messenger RNA (mRNA) metabolism and prevent harmful DNA:RNA hybrids or R-loops. Here, we report that PIWIL4, …
de, us, se, ca, in
(code pays fourni par la source)